Geoff HoultonSophiris BioSHS.TOTRADEMar 26, 2008

A drug that corrects complications that occur with the prostrate and prostrate cancer. Entering phase 2 clinical trials, has large market opportunities. Have done safety studies. In good shape regarding their cash position.

Geoff Houlton

Unknown

Unlock Rating

$0.84

Stock price when the opinion was issued

Consumer Products

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Chris White, CFA

5i Research

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Geoff HoultonSophiris BioSHS.TOTRADEMar 26, 2008

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals